Julia Prabucka-Marciniak
Julia Prabucka-Marciniak has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Edyta Szymańska
Medical University of Warsaw, Warsaw, Poland
8 shared publications - Kacper Kmieć
Miedzylesie Specialist Hospital, Warsaw, Poland
7 shared publications - Mateusz Dembiński
Praski Hospital, Warsaw, Poland
7 shared publications - Michał Bereza
Bródno Masovian Hospital, Warsaw, Poland
7 shared publications - Jakub Pysiewicz
Provincial Hospital in Zgierz, Parzęczewska 35, 95-100 Zgierz, Poland
6 shared publications - Aleksandra Misarko
Bielański Hospital named after Father Jerzy Popiełuszko, 01-809 Warsaw, Poland
3 shared publications
Latest Publications
- Open Access
- 29 September 2025
- Published by Springer Nature in The Cardiothoracic Surgeon
- Vol. 33 (1) , 1-9
Current views on topical tranexamic acid in cardiac surgery—literature and guidelines review
Background: Tranexamic acid (TXA) is commonly utilized across multiple medical fields. This review evaluates the efficacy of its topical administration in cardiac surgery. Main body of the A comprehensive search of the PubMed database has been conducted using the keywords “tranexamic acid local cardiac surgery” and “tranexamic acid topical cardiac surgery.” In addition to PubMed, other relevant sources were reviewed, resulting in the selection of 23 meta-analyses, systematic reviews, and randomized controlled trials. This review evaluates the efficacy of topical TXA compared to intravenous (IV) TXA alone, saline, and the combination of IV and topical TXA in adult patients undergoing cardiac surgery. Results: In comparisons with placebo, topical TXA reduced postoperative blood loss; however, its impact on transfusion rates remains unclear. When compared to IV TXA, topical administration demonstrated similar efficacy in minimizing blood loss and was associated with a lower risk of postoperative seizures. However, topical TXA was linked to a higher incidence of blood transfusions. Studies comparing combined topical and IV TXA with IV administration alone reported no significant differences in blood loss or transfusion rates. Variability in patient populations and study protocols limited the ability to make direct comparisons. In off-pump coronary artery bypass grafting (OPCAB), topical TXA may reduce postoperative blood loss, but no studies have directly compared its effectiveness to IV TXA in this context. Furthermore, graft patency, a critical measure for assessing the safety of antifibrinolytic agents, was not evaluated. Conclusions: Topical TXA has shown promising results in reducing blood loss after cardiac procedures. Nevertheless, further research is needed due to the significant heterogeneity and limited sample sizes in existing studies. Current clinical guidelines indicate that topical TXA is less effective than IV TXA for reducing transfusion requirements, suggesting that topical TXA should not be administered routinely in every case (Class III, Level B). Topical TXA may be considered when standard hemostatic methods are insufficient (Class II, Level B). Furthermore, guidelines recommend the use of topical TXA after cardiopulmonary bypass (CBP) to decrease postoperative drainage and transfusion requirements (Class IIA, Level B-R).
- 29 September 2025
- Published by Springer Nature in The Cardiothoracic Surgeon
- Vol. 33 (1) , 1-9
Open AccessCurrent views on topical tranexamic acid in cardiac surgery—literature and guidelines review
Background: Tranexamic acid (TXA) is commonly utilized across multiple medical fields. This review evaluates the efficacy of its topical administration in cardiac surgery. Main body of the A comprehensive search of the PubMed database has been conducted using the keywords “tranexamic acid local cardiac surgery” and “tranexamic acid topical cardiac surgery.” In addition to PubMed, other relevant sources were reviewed, resulting in the selection of 23 meta-analyses, systematic reviews, and randomized controlled trials. This review evaluates the efficacy of topical TXA compared to intravenous (IV) TXA alone, saline, and the combination of IV and topical TXA in adult patients undergoing cardiac surgery. Results: In comparisons with placebo, topical TXA reduced postoperative blood loss; however, its impact on transfusion rates remains unclear. When compared to IV TXA, topical administration demonstrated similar efficacy in minimizing blood loss and was associated with a lower risk of postoperative seizures. However, topical TXA was linked to a higher incidence of blood transfusions. Studies comparing combined topical and IV TXA with IV administration alone reported no significant differences in blood loss or transfusion rates. Variability in patient populations and study protocols limited the ability to make direct comparisons. In off-pump coronary artery bypass grafting (OPCAB), topical TXA may reduce postoperative blood loss, but no studies have directly compared its effectiveness to IV TXA in this context. Furthermore, graft patency, a critical measure for assessing the safety of antifibrinolytic agents, was not evaluated. Conclusions: Topical TXA has shown promising results in reducing blood loss after cardiac procedures. Nevertheless, further research is needed due to the significant heterogeneity and limited sample sizes in existing studies. Current clinical guidelines indicate that topical TXA is less effective than IV TXA for reducing transfusion requirements, suggesting that topical TXA should not be administered routinely in every case (Class III, Level B). Topical TXA may be considered when standard hemostatic methods are insufficient (Class II, Level B). Furthermore, guidelines recommend the use of topical TXA after cardiopulmonary bypass (CBP) to decrease postoperative drainage and transfusion requirements (Class IIA, Level B-R).
- Open Access
- 19 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(47))
CLINICAL SPECTRUM AND THERAPEUTIC ADVANCES IN PEDIATRIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematopoietic stem cell disorder driven by somatic PIGA mutations, leading to uncontrolled complement activation, intravascular hemolysis, and thrombotic risk. Pediatric PNH represents fewer than 10% of cases and demonstrates a distinct clinical phenotype that complicates diagnosis and management. Methods: A comprehensive literature search of PubMed, Embase, Web of Science, and Scopus was conducted through July 2025 using predefined keywords related to PNH, pediatrics, bone marrow failure, and complement inhibitors. Eligible studies included clinical trials, registry data, systematic reviews, case series, and case reports. Relevant adult studies were also reviewed when mechanistic or therapeutic insights were applicable to pediatric disease. Data were synthesized narratively, focusing on pathophysiology, clinical spectrum, diagnostic approaches, and therapeutic advances. Results: Pediatric PNH most often presents with bone marrow failure syndromes rather than classic hemolytic features. Hemoglobinuria is infrequent, while cytopenias predominate. Thrombosis, though less common than in adults, remains a serious complication. High-sensitivity flow cytometry enables early and accurate diagnosis, particularly for small clone sizes. Complement inhibitors—including eculizumab, ravulizumab, and crovalimab—have markedly improved survival and reduced morbidity, while emerging agents targeting proximal complement pathways (pegcetacoplan, iptacopan, danicopan) show promise. Hematopoietic cell transplantation remains the only curative option but is reserved for selected patients. Conclusions: Pediatric PNH differs significantly from adult disease in presentation and management. Advances in complement inhibition have transformed prognosis, but further pediatric-specific research and inclusion in clinical trials are urgently needed to establish evidence-based guidelines and optimize long-term outcomes.
- 19 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(47))
Open AccessCLINICAL SPECTRUM AND THERAPEUTIC ADVANCES IN PEDIATRIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematopoietic stem cell disorder driven by somatic PIGA mutations, leading to uncontrolled complement activation, intravascular hemolysis, and thrombotic risk. Pediatric PNH represents fewer than 10% of cases and demonstrates a distinct clinical phenotype that complicates diagnosis and management. Methods: A comprehensive literature search of PubMed, Embase, Web of Science, and Scopus was conducted through July 2025 using predefined keywords related to PNH, pediatrics, bone marrow failure, and complement inhibitors. Eligible studies included clinical trials, registry data, systematic reviews, case series, and case reports. Relevant adult studies were also reviewed when mechanistic or therapeutic insights were applicable to pediatric disease. Data were synthesized narratively, focusing on pathophysiology, clinical spectrum, diagnostic approaches, and therapeutic advances. Results: Pediatric PNH most often presents with bone marrow failure syndromes rather than classic hemolytic features. Hemoglobinuria is infrequent, while cytopenias predominate. Thrombosis, though less common than in adults, remains a serious complication. High-sensitivity flow cytometry enables early and accurate diagnosis, particularly for small clone sizes. Complement inhibitors—including eculizumab, ravulizumab, and crovalimab—have markedly improved survival and reduced morbidity, while emerging agents targeting proximal complement pathways (pegcetacoplan, iptacopan, danicopan) show promise. Hematopoietic cell transplantation remains the only curative option but is reserved for selected patients. Conclusions: Pediatric PNH differs significantly from adult disease in presentation and management. Advances in complement inhibition have transformed prognosis, but further pediatric-specific research and inclusion in clinical trials are urgently needed to establish evidence-based guidelines and optimize long-term outcomes.
- Open Access
- 17 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(47))
SPECIAL CONSIDERATIONS IN THE DIAGNOSIS AND MANAGEMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for a variety of pediatric hematologic and non-malignant disorders, yet chronic graft-versus-host disease (cGVHD) remains the primary cause of long-term non-relapse morbidity and mortality. The incidence of cGVHD in children has been increasing, a trend associated with the expanded use of peripheral blood stem cells and unrelated donors. Despite generally lower rates than adults, cGVHD remains a significant and growing clinical problem with profound long-term implications for pediatric survivors, who have a much greater life expectancy. Objective: This review aims to provide a focused and much-needed overview of cGVHD in children. Specifically, it delineates the unique epidemiological, pathobiological, and clinical characteristics that distinguish the disease in this population, including immunological distinctions, diagnostic challenges, and special considerations for long-term effects. This report highlights the pressing questions in treatment and research, addressing the historical lack of specialized data and emphasizing the principle that "children are not small adults" in the context of this complex condition. Methods: This review was conducted by systematically analyzing and synthesizing peer-reviewed articles, clinical guidelines, and consensus statements related to pediatric cGVHD. A comprehensive literature search was performed across databases including PubMed, Scopus, and Embase using a combination of keywords such as "pediatric," "chronic GvHD," "children," "hematopoietic stem cell transplantation," "management," "diagnosis," and "long-term effects." Summary: The lower incidence and severity of cGVHD in children are attributable to distinct biological factors, including superior thymic function and a greater use of bone marrow or cord blood grafts. However, diagnostic challenges persist due to non-specific symptoms and the limitations of adult-derived criteria. The profound and age-specific impacts of the disease and its treatments on growth, neurocognitive development, and infectious risk underscore the disproportionate long-term burden on pediatric survivors. The review discusses therapeutic strategies that prioritize steroid-sparing regimens and the integration of novel targeted inhibitors and cellular therapies. Conclusion: A paradigm shift is necessary, advocating for dedicated pediatric research, age-adapted diagnostic tools, and a multidisciplinary, holistic approach to long-term survivorship care to optimize the functional status and quality of life for children with cGVHD.
- 17 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(47))
Open AccessSPECIAL CONSIDERATIONS IN THE DIAGNOSIS AND MANAGEMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for a variety of pediatric hematologic and non-malignant disorders, yet chronic graft-versus-host disease (cGVHD) remains the primary cause of long-term non-relapse morbidity and mortality. The incidence of cGVHD in children has been increasing, a trend associated with the expanded use of peripheral blood stem cells and unrelated donors. Despite generally lower rates than adults, cGVHD remains a significant and growing clinical problem with profound long-term implications for pediatric survivors, who have a much greater life expectancy. Objective: This review aims to provide a focused and much-needed overview of cGVHD in children. Specifically, it delineates the unique epidemiological, pathobiological, and clinical characteristics that distinguish the disease in this population, including immunological distinctions, diagnostic challenges, and special considerations for long-term effects. This report highlights the pressing questions in treatment and research, addressing the historical lack of specialized data and emphasizing the principle that "children are not small adults" in the context of this complex condition. Methods: This review was conducted by systematically analyzing and synthesizing peer-reviewed articles, clinical guidelines, and consensus statements related to pediatric cGVHD. A comprehensive literature search was performed across databases including PubMed, Scopus, and Embase using a combination of keywords such as "pediatric," "chronic GvHD," "children," "hematopoietic stem cell transplantation," "management," "diagnosis," and "long-term effects." Summary: The lower incidence and severity of cGVHD in children are attributable to distinct biological factors, including superior thymic function and a greater use of bone marrow or cord blood grafts. However, diagnostic challenges persist due to non-specific symptoms and the limitations of adult-derived criteria. The profound and age-specific impacts of the disease and its treatments on growth, neurocognitive development, and infectious risk underscore the disproportionate long-term burden on pediatric survivors. The review discusses therapeutic strategies that prioritize steroid-sparing regimens and the integration of novel targeted inhibitors and cellular therapies. Conclusion: A paradigm shift is necessary, advocating for dedicated pediatric research, age-adapted diagnostic tools, and a multidisciplinary, holistic approach to long-term survivorship care to optimize the functional status and quality of life for children with cGVHD.
- Open Access
- 16 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(47))
CURRENT PERSPECTIVES ON THE MANAGEMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC TRANSPLANTATION
Background: Hematopoietic stem cell transplantation (HSCT) has expanded its scope as a curative therapy for a wide range of severe pediatric diseases. However, its efficacy is frequently challenged by graft-versus-host disease (GVHD), a significant and potentially fatal complication. This is particularly relevant in the pediatric population, where unique immunological and physiological factors contribute to a distinct disease course. Objective: This narrative review synthesizes the current evidence base on the treatment and management of GVHD in pediatric patients. It aims to provide a critical appraisal of the unique immunological determinants, current prophylactic and treatment interventions, and the long-term morbidities and clinical needs for this specific field. Methods: A comprehensive systematic search of databases, including PubMed, Embase, and the Cochrane Library, was conducted to identify relevant literature. Articles were selected based on inclusion criteria focusing on GVHD management in patients aged 18 or younger, while excluding non-peer-reviewed articles and case reports. Data on study design, patient populations, treatment regimens, and key outcomes were extracted and synthesized. Summary: The pathogenesis of acute GVHD (aGVHD) is described by the classic three-phase model, beginning with host tissue damage, followed by donor T-cell activation, and culminating in targeted organ destruction, particularly in the skin, liver, and gastrointestinal tract. Diagnostic methods have evolved from clinical and histological assessments to include advanced biomarker-driven approaches, such as the MAGIC algorithm, which provides more precise prognostic risk stratification. Current prophylaxis strategies primarily involve calcineurin inhibitors in combination with methotrexate or mycophenolate mofetil. Novel agents like ruxolitinib and vedolizumab are emerging as promising therapeutic tools for both prophylaxis and the treatment of steroid-refractory disease. Despite these advancements, significant clinical gaps persist, as many established guidelines for GVHD management are not tailored to the pediatric population. The evident age-related disparity in GVHD risk highlights the critical need for pediatric-specific research. Conclusion: While substantial progress has been made in understanding and treating GVHD, there is a clear and urgent need for further research focused on pediatric-specific protocols. Continued efforts to validate existing therapies in pediatric cohorts, explore novel agents, and leverage biomarkers are essential to improve outcomes and the quality of life for young patients undergoing HSCT.
- 16 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(47))
Open AccessCURRENT PERSPECTIVES ON THE MANAGEMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC TRANSPLANTATION
Background: Hematopoietic stem cell transplantation (HSCT) has expanded its scope as a curative therapy for a wide range of severe pediatric diseases. However, its efficacy is frequently challenged by graft-versus-host disease (GVHD), a significant and potentially fatal complication. This is particularly relevant in the pediatric population, where unique immunological and physiological factors contribute to a distinct disease course. Objective: This narrative review synthesizes the current evidence base on the treatment and management of GVHD in pediatric patients. It aims to provide a critical appraisal of the unique immunological determinants, current prophylactic and treatment interventions, and the long-term morbidities and clinical needs for this specific field. Methods: A comprehensive systematic search of databases, including PubMed, Embase, and the Cochrane Library, was conducted to identify relevant literature. Articles were selected based on inclusion criteria focusing on GVHD management in patients aged 18 or younger, while excluding non-peer-reviewed articles and case reports. Data on study design, patient populations, treatment regimens, and key outcomes were extracted and synthesized. Summary: The pathogenesis of acute GVHD (aGVHD) is described by the classic three-phase model, beginning with host tissue damage, followed by donor T-cell activation, and culminating in targeted organ destruction, particularly in the skin, liver, and gastrointestinal tract. Diagnostic methods have evolved from clinical and histological assessments to include advanced biomarker-driven approaches, such as the MAGIC algorithm, which provides more precise prognostic risk stratification. Current prophylaxis strategies primarily involve calcineurin inhibitors in combination with methotrexate or mycophenolate mofetil. Novel agents like ruxolitinib and vedolizumab are emerging as promising therapeutic tools for both prophylaxis and the treatment of steroid-refractory disease. Despite these advancements, significant clinical gaps persist, as many established guidelines for GVHD management are not tailored to the pediatric population. The evident age-related disparity in GVHD risk highlights the critical need for pediatric-specific research. Conclusion: While substantial progress has been made in understanding and treating GVHD, there is a clear and urgent need for further research focused on pediatric-specific protocols. Continued efforts to validate existing therapies in pediatric cohorts, explore novel agents, and leverage biomarkers are essential to improve outcomes and the quality of life for young patients undergoing HSCT.
- Open Access
- 4 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
THE ROLE OF PRECISION MEDICINE AND GENOMICS IN CARDIAC SURGERY
Background: Precision medicine, driven by advances in genomics, is reshaping the approach to diagnosis, risk assessment, and treatment planning in cardiac surgery. By analyzing genetic variation and molecular pathways, clinicians can move beyond standardized protocols toward individualized surgical care. Methods: This review synthesizes recent literature on the integration of genomic technologies - such as whole genome sequencing, gene expression profiling, and pharmacogenomics - into the preoperative, intraoperative, and postoperative phases of cardiac surgery. Sources include peer-reviewed articles, clinical trial data, and translational research reports published over the past 20 years. Results: Genomic profiling enables improved risk stratification, early detection of hereditary cardiovascular diseases, and identification of genetic biomarkers predictive of surgical outcomes. Pharmacogenomic insights allow optimization of perioperative drug therapy, reducing complications and enhancing recovery. Emerging applications include bioinformatics-driven surgical planning and integration of multi-omic data for real-time decision support. However, challenges remain regarding data interpretation, ethical considerations, and integration into clinical workflows. Conclusion: Precision medicine and genomics hold significant promise for improving patient-specific outcomes in cardiac surgery. Their successful implementation will require robust clinical evidence, interdisciplinary collaboration, and infrastructure to manage and interpret complex genomic data. Ongoing research is likely to expand their role from risk prediction to fully individualized surgical strategies.
- 4 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
Open AccessTHE ROLE OF PRECISION MEDICINE AND GENOMICS IN CARDIAC SURGERY
Background: Precision medicine, driven by advances in genomics, is reshaping the approach to diagnosis, risk assessment, and treatment planning in cardiac surgery. By analyzing genetic variation and molecular pathways, clinicians can move beyond standardized protocols toward individualized surgical care. Methods: This review synthesizes recent literature on the integration of genomic technologies - such as whole genome sequencing, gene expression profiling, and pharmacogenomics - into the preoperative, intraoperative, and postoperative phases of cardiac surgery. Sources include peer-reviewed articles, clinical trial data, and translational research reports published over the past 20 years. Results: Genomic profiling enables improved risk stratification, early detection of hereditary cardiovascular diseases, and identification of genetic biomarkers predictive of surgical outcomes. Pharmacogenomic insights allow optimization of perioperative drug therapy, reducing complications and enhancing recovery. Emerging applications include bioinformatics-driven surgical planning and integration of multi-omic data for real-time decision support. However, challenges remain regarding data interpretation, ethical considerations, and integration into clinical workflows. Conclusion: Precision medicine and genomics hold significant promise for improving patient-specific outcomes in cardiac surgery. Their successful implementation will require robust clinical evidence, interdisciplinary collaboration, and infrastructure to manage and interpret complex genomic data. Ongoing research is likely to expand their role from risk prediction to fully individualized surgical strategies.
- Open Access
- 3 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
BIOMARKERS IN VASCULAR SURGERY: PREDICTING GRAFT FAILURE AND RESTENOSIS
Vascular diseases are a major source of global morbidity and mortality, often requiring surgical intervention, but the long-term outcomes are frequently compromised by complications like graft failure and restenosis. Since traditional imaging methods often detect these issues only at an advanced stage, there is a critical need for more precise and earlier risk prediction tools. This comprehensive narrative review synthesizes existing literature on the predictive value of circulating and tissue-based biomarkers for these adverse outcomes. The study systematically examined major electronic databases including PubMed, Scopus, and Web of Science, utilizing keywords related to vascular surgery, outcomes (e.g., graft failure, restenosis), and biomarkers. The identified biomarkers were categorized into four principal groups: inflammatory, lipid-related, genetic, and novel/emerging markers. The review found that elevated levels of inflammatory markers—such as high-sensitivity C-reactive protein (hs-CRP) and various interleukins (IL-6, IL-1β, TNF-α, IL-18, IL-33)—are strongly associated with an increased risk of graft failure and restenosis. Conversely, anti-inflammatory interleukins like IL-10 and IL-19 were found to correlate with a reduced risk. Furthermore, an unfavorable lipid profile (high LDL, low HDL, or an elevated LDL/HDL ratio) was consistently linked to a higher incidence of these complications. The review also highlights the promising potential of genetic markers, such as specific single nucleotide polymorphisms (SNPs), and novel biomarkers like non-coding RNAs in developing personalized treatment strategies. The findings suggest that incorporating biomarker panels into routine clinical practice could significantly enhance preoperative risk stratification, enabling tailored perioperative therapy and more effective postoperative surveillance. By allowing for the early detection of biological evidence of graft compromise, this precision-medicine model has the potential to substantially improve long-term patient outcomes in vascular surgery.
- 3 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
Open AccessBIOMARKERS IN VASCULAR SURGERY: PREDICTING GRAFT FAILURE AND RESTENOSIS
Vascular diseases are a major source of global morbidity and mortality, often requiring surgical intervention, but the long-term outcomes are frequently compromised by complications like graft failure and restenosis. Since traditional imaging methods often detect these issues only at an advanced stage, there is a critical need for more precise and earlier risk prediction tools. This comprehensive narrative review synthesizes existing literature on the predictive value of circulating and tissue-based biomarkers for these adverse outcomes. The study systematically examined major electronic databases including PubMed, Scopus, and Web of Science, utilizing keywords related to vascular surgery, outcomes (e.g., graft failure, restenosis), and biomarkers. The identified biomarkers were categorized into four principal groups: inflammatory, lipid-related, genetic, and novel/emerging markers. The review found that elevated levels of inflammatory markers—such as high-sensitivity C-reactive protein (hs-CRP) and various interleukins (IL-6, IL-1β, TNF-α, IL-18, IL-33)—are strongly associated with an increased risk of graft failure and restenosis. Conversely, anti-inflammatory interleukins like IL-10 and IL-19 were found to correlate with a reduced risk. Furthermore, an unfavorable lipid profile (high LDL, low HDL, or an elevated LDL/HDL ratio) was consistently linked to a higher incidence of these complications. The review also highlights the promising potential of genetic markers, such as specific single nucleotide polymorphisms (SNPs), and novel biomarkers like non-coding RNAs in developing personalized treatment strategies. The findings suggest that incorporating biomarker panels into routine clinical practice could significantly enhance preoperative risk stratification, enabling tailored perioperative therapy and more effective postoperative surveillance. By allowing for the early detection of biological evidence of graft compromise, this precision-medicine model has the potential to substantially improve long-term patient outcomes in vascular surgery.
- Open Access
- 25 August 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
TRANEXAMIC ACID IN PEDIATRIC CARDIAC SURGERY: A COMPREHENSIVE REVIEW OF EFFICACY, SAFETY, AND CURRENT CONTROVERSIES
Pediatric patients undergoing cardiac surgery, particularly with cardiopulmonary bypass (CPB), are at high risk for significant bleeding and allogeneic blood transfusions due to their unique hemostatic profile. Tranexamic acid (TXA) is the primary antifibrinolytic agent used to mitigate this risk, but its efficacy, safety, and optimal administration in this population remain topics of debate. This article provides a comprehensive review and to synthesize the available evidence and identify critical knowledge gaps. Our analysis confirms that TXA significantly reduces postoperative blood loss and the need for allogeneic red blood cell and fresh frozen plasma transfusions. This effect was particularly notable in high-risk subgroups such as infants and cyanotic patients. Substantial heterogeneity was found across studies, primarily related to varying TXA dosing regimens and differing transfusion protocols, which limited the ability to define a single optimal dose. TXA is an effective agent for reducing bleeding and transfusion needs in pediatric cardiac surgery, but its use is associated with a potential, dose-dependent risk of seizures. The wide variability in dosing regimens and the lack of robust data on long-term neurological outcomes highlight a critical need for future large-scale, prospective trials. These studies should aim to standardize dosing protocols and definitively assess the true benefit-to-risk ratio of TXA in specific pediatric subgroups.
- 25 August 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
Open AccessTRANEXAMIC ACID IN PEDIATRIC CARDIAC SURGERY: A COMPREHENSIVE REVIEW OF EFFICACY, SAFETY, AND CURRENT CONTROVERSIES
Pediatric patients undergoing cardiac surgery, particularly with cardiopulmonary bypass (CPB), are at high risk for significant bleeding and allogeneic blood transfusions due to their unique hemostatic profile. Tranexamic acid (TXA) is the primary antifibrinolytic agent used to mitigate this risk, but its efficacy, safety, and optimal administration in this population remain topics of debate. This article provides a comprehensive review and to synthesize the available evidence and identify critical knowledge gaps. Our analysis confirms that TXA significantly reduces postoperative blood loss and the need for allogeneic red blood cell and fresh frozen plasma transfusions. This effect was particularly notable in high-risk subgroups such as infants and cyanotic patients. Substantial heterogeneity was found across studies, primarily related to varying TXA dosing regimens and differing transfusion protocols, which limited the ability to define a single optimal dose. TXA is an effective agent for reducing bleeding and transfusion needs in pediatric cardiac surgery, but its use is associated with a potential, dose-dependent risk of seizures. The wide variability in dosing regimens and the lack of robust data on long-term neurological outcomes highlight a critical need for future large-scale, prospective trials. These studies should aim to standardize dosing protocols and definitively assess the true benefit-to-risk ratio of TXA in specific pediatric subgroups.
- Open Access
- 31 July 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 3(47)
HEAD AND NECK SOFT TISSUE SARCOMAS: DIAGNOSIS AND MANAGEMENT REVIEW
Soft tissue sarcomas (STS) of the head and neck are rare and histologically diverse malignancies that present unique diagnostic and therapeutic challenges due to their proximity to critical anatomical structures. They originate from various tissues, including fat, muscle, nerves, blood vessels, and others. Although they account for a small proportion of all STS, their management requires individualized care within experienced sarcoma centres. While surgery and radiotherapy remain the primary modalities, newer systemic and targeted strategies are increasingly being incorporated into clinical practice. In this review we summarise current state of knowledge related to the diagnosis, staging, and treatment of head and neck STS in adults. We also discuss evolving systemic and targeted therapies with potential relevance to clinical oncology practice.
- 31 July 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 3(47)
Open AccessHEAD AND NECK SOFT TISSUE SARCOMAS: DIAGNOSIS AND MANAGEMENT REVIEW
Soft tissue sarcomas (STS) of the head and neck are rare and histologically diverse malignancies that present unique diagnostic and therapeutic challenges due to their proximity to critical anatomical structures. They originate from various tissues, including fat, muscle, nerves, blood vessels, and others. Although they account for a small proportion of all STS, their management requires individualized care within experienced sarcoma centres. While surgery and radiotherapy remain the primary modalities, newer systemic and targeted strategies are increasingly being incorporated into clinical practice. In this review we summarise current state of knowledge related to the diagnosis, staging, and treatment of head and neck STS in adults. We also discuss evolving systemic and targeted therapies with potential relevance to clinical oncology practice.
- Open Access
- 30 July 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 3(47)
MANAGEMENT OF ACUTE ISCHEMIC STROKE IN PEDIATRIC PATIENTS: CLINICAL METHODS AND OUTCOMES
Background: Acute ischemic stroke (AIS) in the pediatric population is a rare condition. Despite its severe outcomes—including long-term neurological deficits and mortality— diagnosis of pediatric AIS is often delayed. In contrast to adult AIS, evidence-based guidelines for the pediatric population are limited, primarily due to the absence of data from multicenter randomized clinical trials. Aim: This review aims to present a comprehensive overview of the treatment methods of AIS in children, focusing on thrombolysis, mechanical thrombectomy, and supportive neuroprotective strategies. Material and Methods: An in-depth literature review was performed using PubMed, ScienceDirect, and Google Scholar, including keywords such as: “pediatric acute ischemic stroke”, “PAIS”, “acute ischemic stroke in children”, “acute ischemic stroke management”, “tenecteplase”, “thrombolysis in children” Results: Intravenous thrombolysis with alteplase (0.9 mg/kg) may be considered in children ≥2 years of age within 4.5 hours of symptom onset, although data are still limited due to poor patient enrollment in the Thrombolysis in Pediatric Stroke Study (TIPS). Mechanical thrombectomy may be effective, even beyond the 6-hour window, particularly in cases involving large-vessel occlusion. Neuroprotective measures—such as glucose, temperature, and blood pressure control—may contribute to improved outcomes. For secondary prevention, antiplatelet or anticoagulant therapy is recommended. Conclusions: Management of AIS in children still relies on extrapolated adult data. There is an urgent need for pediatric-specific clinical trials to establish evidence-based treatment protocols and guidelines. In the meantime, early diagnosis, reperfusion strategies, and supportive neuroprotective measures appear to be critical.
- 30 July 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 3(47)
Open AccessMANAGEMENT OF ACUTE ISCHEMIC STROKE IN PEDIATRIC PATIENTS: CLINICAL METHODS AND OUTCOMES
Background: Acute ischemic stroke (AIS) in the pediatric population is a rare condition. Despite its severe outcomes—including long-term neurological deficits and mortality— diagnosis of pediatric AIS is often delayed. In contrast to adult AIS, evidence-based guidelines for the pediatric population are limited, primarily due to the absence of data from multicenter randomized clinical trials. Aim: This review aims to present a comprehensive overview of the treatment methods of AIS in children, focusing on thrombolysis, mechanical thrombectomy, and supportive neuroprotective strategies. Material and Methods: An in-depth literature review was performed using PubMed, ScienceDirect, and Google Scholar, including keywords such as: “pediatric acute ischemic stroke”, “PAIS”, “acute ischemic stroke in children”, “acute ischemic stroke management”, “tenecteplase”, “thrombolysis in children” Results: Intravenous thrombolysis with alteplase (0.9 mg/kg) may be considered in children ≥2 years of age within 4.5 hours of symptom onset, although data are still limited due to poor patient enrollment in the Thrombolysis in Pediatric Stroke Study (TIPS). Mechanical thrombectomy may be effective, even beyond the 6-hour window, particularly in cases involving large-vessel occlusion. Neuroprotective measures—such as glucose, temperature, and blood pressure control—may contribute to improved outcomes. For secondary prevention, antiplatelet or anticoagulant therapy is recommended. Conclusions: Management of AIS in children still relies on extrapolated adult data. There is an urgent need for pediatric-specific clinical trials to establish evidence-based treatment protocols and guidelines. In the meantime, early diagnosis, reperfusion strategies, and supportive neuroprotective measures appear to be critical.